Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2275-2282

  Begemann, Martin ^a,d   Kashimawo, Sharafadeen A ^a   Heitjan, Daniel F ^c   Schiff, Peter B ^b   Bruce, Jeffrey N ^b   Weinstein, I Bernard ^a,c  

^a Department of Medicine

^b Department of Radiation Oncology ^*

^c Department of Orthopaedic Surgery   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CDC2; CDK2; Cell cycle; CGP 41251; Protein kinase C; Radiosensitization

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; HISTONE H1; MIDOSTAURIN; PROTAMINE KINASE; RADIOSENSITIZING AGENT; STAUROSPORINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; ENZYME INHIBITION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN CELL; METAPHASE; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CELL CYCLE; CELL SURVIVAL; CESIUM RADIOISOTOPES; CLONE CELLS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, RADIATION; G2 PHASE; GLIOBLASTOMA; HUMANS; MITOSIS; PROTAMINE KINASE; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0031811054     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Marte BM, Meyer T, Stabel S, Standke GJR, Jakenr S, Fabbro D and Hynes NE: Protein kinase C and mammary cell differentiation: Involvement of protein kinase Ca in the induction of ß-casein expression. Cell Growth Diff 5: 239-247, 1994.
2. Andrejauskas-Buchdunger E and Regenass U: Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res 52: 5353-5358, 1992.
3. Begemann M, Kashimawo SA, Choi YJA, Kim S, Christiansen KM, Duigou G, Mueller M, Schieren I, Ghosh S, Fabbro D, Lampen NM, Schiff PB, Bruce JN and Weinstein IB: Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C and by a phorbol ester tumor promoter. Clin Cancer Res 2: 1017-1030, 1996.
4. Meyer T, Regenass U, Fabbro D, Alteri E, Roesel J, Mueller M, Caravatti G, and Matter A: A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 43: 851-856, 1989.
5. van den Heuvel S and Harlow E: Distinct roles for cyclin-dependent kinases in cell-cycle control. Science 262: 2050-2054, 1993.
6. King RW, Jackson PK and Kirschner MW: Mitosis in transition. Cell 79: 563-571, 1994.
7. Hunter T and Pines J: Cyclins and Cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
8. Sinclair WK and Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Rad Res 29: 450-474, 1966.
9. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR and Reed SI: A novel inhibitor of cyclin-cdk activity detected in transforming growth factor ß-arrested epithelial cells. Mol Cell Biol 14: 3683-3694, 1994.
10. Ausubel FA, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA. and Struhl K (eds.) Current Protocols in Molecular Biology. New York: Greene and Wiley-Interscience, 1990.
11. Tishler RB, Reard CR, Hall EJ and Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497, 1992.
12. Traganos F, Gong J, Ardelt B and Darzynkiewicz Z: Effect of staurosporine on MOLT-4 cell progression through GT and on cytokinesis. J Cell Physiol 158: 535-544, 1994.
13. Solomon MJ: The functions of CAK, the p34cdc2-activating kinase. TIBS 19: 496-500, 1994.
14. Seufert W, Futcher B and Jentsch S; Role of a ubiquitin-conjugated enzyme in degradation of S-and M-phase cyclins. Nature 373: 78-81, 1995.
15. King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P and Kirschner MW: A 20 S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81: 279-288, 1995.
16. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA., Raju SM, Smulson ME, Yamin T-T, Yu VL and Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
17. Guadagno TM and Newport JW: Cdk2 kinase is required for entry into mitosis as a positive regulator of cdc2-cyclin B kinase activity. Cell 84: 73-82, 1996.
18. Gadbois DM, Hamaguchi JR, Swank RA and Bradbury EM: Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem Biophys Res Comm 184: 80-85, 1992.
19. Abe K, Yoshida M, Usui T, Horinouchi S and Beppu T: Highly synchronous culture of fibroblasts form G2 block caused by Staurosporine, a potent inhibitor of protein kinases. Exp Cell Res 192: 122-127, 1991.
20. Crissman HA, Gadbois DM, Tobey RA and Bradbury EM: Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc Natl Acad Sci USA 88: 7580-7584, 1991.
21. Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tanaka N and Okuyama A: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8: 2425-2432, 1993.
22. Usui T, Yoshida M, Abe K, Osada H, Isono K and Beppu T: Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. J Cell Biol 115: 1275-1282, 1991.
23. Bojanowski K, Nishio K, Fukuda M, Larsen AK and Saijo N: Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. Biochem Biophys Res Comm 203: 1574-1580, 1994.
24. Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D, Glab N, Goudeau H, Goudeau M, Guerrier P, Houghton P, Hendriks H, Kloareg B, Lippai M, Marie D, Maro B, Meijer L, Mester J, Mulner-Lorillon O, Poulet SA, Schierenberg E., Schutte B, Vaulot D and Verlhac MH: Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 83: 105-120, 1995.
25. Sinclair WK: Cyclic X-ray responses in mammalian cells in vitro. Rad Res 33: 620-643, 1968.
26. Salcman M, Scholtz H, Kaplan RS and Kulik S: Long-term Survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994.
27. Malaise EP, Fertil B, Chavaudra N and Guichard M: Distribution of radiation sensitivities for human tumor cells of specific histological types: Comparison of in vitro to in vivo data. Int J Radiation Oncology Biol Phys 12: 617-624, 1986.
28. Tishler RB, Schiff P, Geard CR and Hall EJ: Taxol: A novel radiation sensitizer. Int J Radiation Oncology Biol Phys 22: 613-617, 1992.
29. Geard CR, Jones JM and Schiff PB: Taxol and Radiation. Monogr Natl Cancer Inst 15: 89-94, 1993.
30. Zhang W, Anker L, Law RE, Hinton DR, Gopalakrishna R, Pu Q, Gundimeda U, Weiss MH and Couldwell WT: Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. Clin Cancer Res 2: 843-846, 1996.
31. Zhang W, Yamada H, Sakai N and Nozawa Y: Sensitization of C6 glioma cells to radiation by staurosporine, a potent protein kinase C inhibitor. J Neuro-Oncol 15: 1-7, 1993.